THE FOOD AND DRUG ADMINISTRATION (FDA) DECLARED THAT THE SHORTAGE OF GLP-1 RECEPTOR AGONISTS HAS BEEN RESOLVED. SEMAGLUTIDE (WEGOVY, OZEMPIC) WAS RESOLVED FEBRUARY 21, 2025 AND TIRZEPATIDE (MOUNJARO, ZEPBOUND) WAS RESOLVED IN OCTOBER 2024. THE FDA IS NOW PHASING OUT TEMPORARY MEASURES THAT ALLOWED COMPOUNDING PHARMACIES TO CREATE GLP-1 MEDICATIONS DURING THE SHORTAGE. AS OF MAY 22, 2025 PHARMACIES MUST STOP MANUFACTURING COMPOUNDED SEMAGLUTIDE, BUT THEY CAN STILL DISPENSE THE MEDICATION THAT HAS ALREADY BEEN PRODUCED UNTIL IT EXPIRES. OUTSOURCING FACILITIES ASSOCIATION (OFA) IS CURRENTLY ENGAGED IN A LEGAL BATTLE WITH THE FDA REGARDING THE DECISION TO REMOVE SEMAGLUTIDE AND TIRZEPATIDE FROM THE DRUG SHORTAGE LIST.
Our services.
-
GLP-1 Injections
It is important to note that compounding pharmacies may use a blend with other supplements (commonly Vitamin B) which lowers the dose and therefore the effectiveness of the medication. This is why many online prescribers can offer such low prices. The end result is slower minimal weight loss and higher doses. Ultimately it will end up costing more money to the consumer over time. There is also infrequent lab monitoring to be mindful of the potential serious side effects.
-
Anoretics
These medications reduce appetite to support less caloric intake leading to weight loss. This includes phentermine, topiramate, naltrexone, orlistat, liraglutide, and bupropion. Often these medication can be prescribed alone or in combination.